Clinical Trial Update: Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

View source ↗

Summary

Takeda's TAK-755 expanded access program for congenital thrombotic thrombocytopenic purpura has been approved for marketing, enabling broader access to the ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Thrombotic Thrombocytopenic Purpura
• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• TAK-755

Snippet

Sponsor: Takeda | Conditions: Thrombotic Thrombocytopenic Purpura (TTP) | Status: APPROVED_FOR_MARKETING